Climb Bio Total Asset vs. Net Income

CLYM Stock   2.82  0.28  9.03%   
Considering Climb Bio's profitability and operating efficiency indicators, Climb Bio may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Climb Bio's ability to earn profits and add value for shareholders.

Climb Bio Total Assets

121.92 Million

For Climb Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Climb Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Climb Bio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Climb Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Climb Bio over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Climb Bio Net Income vs. Total Asset Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Climb Bio's current stock value. Our valuation model uses many indicators to compare Climb Bio value to that of its competitors to determine the firm's financial worth.
Climb Bio is number one stock in total asset category among its peers. It also is number one stock in net income category among its peers . At this time, Climb Bio's Total Assets are very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Climb Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Climb Net Income vs. Total Asset

Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Climb Bio

Total Asset

 = 

Tangible Assets

+

Intangible Assets

 = 
110.47 M
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Climb Bio

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(35.12 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.

Climb Net Income Comparison

Climb Bio is currently under evaluation in net income category among its peers.

Climb Bio Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Climb Bio, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Climb Bio will eventually generate negative long term returns. The profitability progress is the general direction of Climb Bio's change in net profit over the period of time. It can combine multiple indicators of Climb Bio, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-40.3 M-42.3 M
Net Loss-35.1 M-36.9 M
Income Before Tax-35.1 M-36.9 M
Total Other Income Expense Net536 K562.8 K
Net Loss-35.1 M-36.9 M
Net Interest Income4.6 M3.3 M
Interest Income4.6 M3.3 M

Climb Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Climb Bio. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Climb Bio position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Climb Bio's important profitability drivers and their relationship over time.

Use Climb Bio in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Climb Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Climb Bio will appreciate offsetting losses from the drop in the long position's value.

Climb Bio Pair Trading

Climb Bio Pair Trading Analysis

The ability to find closely correlated positions to Climb Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Climb Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Climb Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Climb Bio to buy it.
The correlation of Climb Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Climb Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Climb Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Climb Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Climb Bio position

In addition to having Climb Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Manufacturing Thematic Idea Now

Manufacturing
Manufacturing Theme
Companies that provide goods across residential, commercial and industrial construction such as machinery, tools, or lumber production. The Manufacturing theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Manufacturing Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Climb Bio is a strong investment it is important to analyze Climb Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Climb Bio's future performance. For an informed investment choice regarding Climb Stock, refer to the following important reports:
Check out Trending Equities.
To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
To fully project Climb Bio's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Climb Bio at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Climb Bio's income statement, its balance sheet, and the statement of cash flows.
Potential Climb Bio investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Climb Bio investors may work on each financial statement separately, they are all related. The changes in Climb Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Climb Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.